Zacks: Analysts Anticipate DexCom, Inc. (DXCM) to Post -$0.22 Earnings Per Share

Equities analysts expect DexCom, Inc. (NASDAQ:DXCM) to report ($0.22) earnings per share for the current quarter, according to Zacks Investment Research. Ten analysts have made estimates for DexCom’s earnings, with the highest EPS estimate coming in at ($0.13) and the lowest estimate coming in at ($0.34). DexCom posted earnings per share of ($0.24) during the same quarter last year, which would indicate a positive year-over-year growth rate of 8.3%. The business is expected to announce its next earnings results on Tuesday, August 1st.

According to Zacks, analysts expect that DexCom will report full year earnings of ($0.66) per share for the current fiscal year, with EPS estimates ranging from ($0.84) to ($0.32). For the next financial year, analysts forecast that the business will post earnings of $0.08 per share, with EPS estimates ranging from ($0.35) to $0.36. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that cover DexCom.

DexCom (NASDAQ:DXCM) last posted its earnings results on Tuesday, May 2nd. The medical device company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.06. The company had revenue of $142.30 million during the quarter, compared to analysts’ expectations of $143.94 million. DexCom had a negative net margin of 14.70% and a negative return on equity of 32.94%.

DXCM has been the subject of a number of research reports. B. Riley reiterated a “buy” rating and set a $95.00 target price on shares of DexCom in a research report on Wednesday, March 1st. Jefferies Group LLC increased their target price on shares of DexCom from $80.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday, March 1st. Oppenheimer Holdings, Inc. set a $98.00 target price on shares of DexCom and gave the stock a “buy” rating in a research report on Wednesday, March 1st. Northcoast Research reiterated a “buy” rating on shares of DexCom in a research report on Wednesday, March 1st. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $87.00 target price on shares of DexCom in a research report on Tuesday, April 4th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $90.44.

DexCom (NASDAQ:DXCM) traded down 0.15% during mid-day trading on Thursday, hitting $77.84. 1,357,524 shares of the stock were exchanged. The company’s market capitalization is $6.72 billion. DexCom has a 52 week low of $57.68 and a 52 week high of $96.38. The stock’s 50-day moving average is $71.39 and its 200 day moving average is $74.08.

In other DexCom news, EVP Richard Doubleday sold 3,182 shares of the stock in a transaction that occurred on Thursday, March 23rd. The shares were sold at an average price of $76.38, for a total transaction of $243,041.16. Following the transaction, the executive vice president now directly owns 97,815 shares in the company, valued at $7,471,109.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Terrance H. Gregg sold 15,000 shares of the stock in a transaction that occurred on Thursday, April 20th. The shares were sold at an average price of $74.10, for a total transaction of $1,111,500.00. Following the transaction, the insider now owns 454,559 shares in the company, valued at $33,682,821.90. The disclosure for this sale can be found here. Insiders sold 60,795 shares of company stock worth $4,428,513 over the last ninety days. 1.70% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of DXCM. Livforsakringsbolaget Skandia Omsesidigt acquired a new position in shares of DexCom during the first quarter worth approximately $136,000. IFP Advisors Inc boosted its position in shares of DexCom by 9.3% in the first quarter. IFP Advisors Inc now owns 1,863 shares of the medical device company’s stock worth $158,000 after buying an additional 159 shares during the last quarter. Edmond DE Rothschild Holding S.A. acquired a new position in shares of DexCom during the first quarter worth approximately $164,000. Mn Services Vermogensbeheer B.V. boosted its position in shares of DexCom by 3.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,254 shares of the medical device company’s stock worth $179,000 after buying an additional 83 shares during the last quarter. Finally, Daiwa Securities Group Inc. boosted its position in shares of DexCom by 475.0% in the first quarter. Daiwa Securities Group Inc. now owns 2,300 shares of the medical device company’s stock worth $195,000 after buying an additional 1,900 shares during the last quarter.

TRADEMARK VIOLATION NOTICE: “Zacks: Analysts Anticipate DexCom, Inc. (DXCM) to Post -$0.22 Earnings Per Share” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://sportsperspectives.com/2017/06/20/zacks-analysts-anticipate-dexcom-inc-dxcm-to-post-0-22-earnings-per-share.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Get a free copy of the Zacks research report on DexCom (DXCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply